Topic
Biosimilars
854 published works
Big Molecule Watch
Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars
By Yoko Bian
On August 21, 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical (“Lotus”) for AVT34, a proposed biosimilar to IMFINZI® (durvalumab), and AVT87, a proposed biosimilar to HEMLIBRA®…
Big Molecule Watch
Biocon Announces Supplemental U.S. FDA Approval for Prefilled Autoinjector for YESINTEK
On August 18, 2026, Biocon Ltd. (“Biocon”) announced that its U.S. subsidiary has received supplemental U.S. FDA approval for YESINTEK® (ustekinumab-kfce) in a single-dose prefilled autoinjector, 45 mg/0.5 mL and…
Big Molecule Watch
Takeda Files BPCIA Suit Against Polpharma Biologics For Vedolizumab Biosimilar
On August 26, 2026, Takeda Pharmaceuticals USA, Inc. and Takeda Pharmaceuticals International AG (collectively, “Takeda”) filed a BPCIA complaint in the U.S. District Court for the District of New Jersey…
Big Molecule Watch
Biocon Launches Aflibercept Biosimilar in the United States
On August 3, 2026, Biocon Limited announced the commercial launch of its biosimilar YESAFILI (aflibercept-jbvf) in the United States. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor that is…
Big Molecule Watch
Amneal Completes Acquisition of Kashiv
By Jeremy Jones
On August 10, 2026, Amneal Pharmaceuticals, Inc. completed its acquisition of Kashiv BioSciences, LLC. According to Amneal, the acquisition results in “a fully integrated global biosimilars leader with end-to-end capabilities…
Big Molecule Watch
Fresenius Kabi and Dr. Reddy’s Announce FDA Approval of Rituximab Biosimilar
By Sam Herron
On August 1, 2026, Fresenius Kabi and Dr. Reddy’s Laboratories announced that the FDA had approved Dr. Reddy’s rituximab biosimilar, a biosimilar to Genentech’s RITUXAN® (rituximab). Rituximab is a monoclonal…
Big Molecule Watch
Genentech Files BPCIA Patent Infringement Suit Against Biocon Over Proposed PERJETA Biosimilar
By Sarah Adam
On July 29, 2026, Genentech, Inc. (“Genentech”) and Hoffmann-La Roche Inc. filed a complaint in the U.S. District Court for the District of New Jersey against Biocon Biologics Inc. (“Biocon”)…
Big Molecule Watch
FDA Approves Meitheal Pharmaceuticals’ Insulin Aspart Biosimilar GARZULYS
On July 30, 2026, Meitheal Pharmaceuticals, Inc. (“Meitheal”) announced that the U.S. Food and Drug Administration (“FDA”) has approved GARZULYS (insulin apsart-fsan) injection. GARZULYS, a biosimilar to Novo Nordisk’s NOVOLOG®…
Big Molecule Watch
Celltrion Targets European Secukinumab Market with EMA Filing for CT-P55
By Wendy Leben
Celltrion has submitted a Marketing Authorization Application to the European Medicines Agency (“EMA”) for CT-P55, its biosimilar to Novartis’ COSENTYX® (secukinumab). The application covers all indications held by COSENTYX® in…
Big Molecule Watch
Accord BioPharma Launches OSVYRTI® and JUBEREQ® Denosumab Biosimilars
By Tara Thigpen
On July 23, 2026, Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., announced the commercial launch of OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu), FDA-approved interchangeable biosimilars to Amgen’s PROLIA®…